Transforming Biopharma
The state of digital health: What’s next for consumers and biopharma with Ahmed Albaiti
When we use the terms digital health or digital medicine, what do we really mean? Host Maria Whitman takes up this question with Ahmed Albaiti, Head of Digital and Connected Health at ZS. Albaiti, who previously founded and led Medullan, has more than 20 years of experience in the industry. He brings his unique perspective to discuss the state of digital health today and how its next wave may impact both consumers and biopharma.
Highlights from the episode:
- Defining virtual care, digital health and digital medicine in today’s ecosystem
- As digital health becomes more accessible, will consumers get on board?
- Advice for biopharma companies that want to move into digital health
When we use the terms digital health or digital medicine, what do we really mean? Host Maria Whitman takes up this question with Ahmed Albaiti, Head of Digital and Connected Health at ZS. Albaiti, who previously founded and led Medullan, has more than 20 years of experience in the industry. He brings his unique perspective to discuss the state of digital health today and how its next wave may impact both consumers and biopharma.
Highlights from the episode:
- Defining virtual care, digital health and digital medicine in today’s ecosystem
- As digital health becomes more accessible, will consumers get on board?
- Advice for biopharma companies that want to move into digital health